Hot Features
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-con... Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0182 | -1.73333333333 | 1.05 | 1.1 | 1 | 384087 | 1.04300671 | CS |
| 4 | -0.0782 | -7.04504504505 | 1.11 | 1.18 | 1 | 341604 | 1.06332722 | CS |
| 12 | -0.2582 | -20.015503876 | 1.29 | 1.71 | 1 | 478443 | 1.31237334 | CS |
| 26 | 0.0718 | 7.47916666667 | 0.96 | 1.71 | 0.89735 | 515640 | 1.19836167 | CS |
| 52 | -0.2682 | -20.6307692308 | 1.3 | 1.71 | 0.88 | 621831 | 1.15681908 | CS |
| 156 | 0.1278 | 14.1371681416 | 0.904 | 3.12 | 0.661 | 414361 | 1.3899157 | CS |
| 260 | -1.5982 | -60.7680608365 | 2.63 | 4.96 | 0.45 | 381411 | 1.68834584 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.